Summary
Background Effective antiviral therapy against the severe acute respiratory syndrome virus 2 (SARS-CoV-2) remains elusive. Convalescent plasma is an anti-viral approach currently under investigation. We aimed to assess the laboratory and clinical parameters of patients with COVID-19 pneumonia treated with convalescent plasma containing high levels of neutralizing anti-SARS-CoV-2 antibodies.
Methods This was a phase IIa, single institution, prospective study, in adults who were hospitalized with SARS-CoV-2 pneumonia in Hackensack, New Jersey. Convalescent donors were selected based on the presence of high titers of neutralizing anti-SARS-CoV-2 antibodies and plasma was collected by plasmapheresis. Liquid fresh irradiated or fresh frozen plasma was administered to patients divided in two clinical tracks based on severity of disease. The primary endpoints included the intubation rates of patients not requiring mechanical ventilation, and the overall survival of patients mechanically ventilated. Secondary endpoints included viral clearance, and laboratory evaluation of pre-infusion immunity, immune transfer, and late immunity.
Findings Between April 15 and June 18, 2020, 47 adult patients were treated: 32 in the non-mechanically ventilated group and 15 in the mechanically ventilated group. All patients had pneumonia and the majority received 400-500 mL of convalescent plasma. Analysis for non-mechanically ventilated patients showed an intubation rate of 15.6% (95% CI: 5.3%-32.8%) and a day-30 discharged alive rate of 87.1% (95% CI:71%-96.5%). The rate of negative nasopharyngeal swab by PR-PCR on treatment day+10 and +30 was 42.9% (95% CI: 24%-63%) and 78% (95% CI: 56%-93%) respectively. Patients mechanically ventilated had a day-30 mortality of 46.7% (95% CI:21.3%-73.4%), with a negative nasopharyngeal swab by PR-PCR at day+10 and +30 of 85.7% (95% CI: 42-100%; n=7) and 100% (95% CI: 63-100%; n=8). Seven patients (15%) had no pre-infusion immunity, and all were found to have anti-SARS-CoV-2 neutralizing titers three days post infusion. All evaluable patients were found to have neutralizing antibodies on day+30 (n=30) and on day+60 (n=12) post treatment. There was no difference in outcomes within the ranges of high anti-viral neutralizing titers used, mostly greater than 1:1000. There was also no difference between fresh or frozen plasma. The only adverse event was a mild rash in one patient.
Interpretation In this study of adult patients hospitalized with SARS-CoV-2 pneumonia, convalescent plasma was safe and conferred effective transfer of immunity while preserving endogenous immune response. Intubation rates, survival and viral clearance rates support the continued evaluation of this anti-viral modality.
Funding This work was supported the COVID Emergency Research Fund #61315, Hackensack University Medical center; by funds provided to the CDI by Activision Publishing Inc, Suez North America, and by NJ Stands Up to COVID.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NTC04343755
Funding Statement
Funding This work was supported the COVID Emergency Research Fund #61315, Hackensack University Medical center; by funds provided to the CDI by Activision Publishing Inc, Suez North America, and by NJ Stands Up to COVID.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Hackensack Meridian Health IRB 340 Kingsland Street Nutley, NJ 07110 201-880-3669 ereseach@hackensackmeridan.org
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
In Manuscript
